Axogen, Inc.

Contributing Author

Recent Articles by Axogen, Inc.

Jan-21	Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock AXGN GlobeNewswire
Jan-21	Axogen Announces Proposed Public Offering of Common Stock AXGN GlobeNewswire
Jan-12	Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025 AXGN -5.85% GlobeNewswire
Dec-17	Axogen, Inc. to Participate in the J.P. Morgan 2026 Healthcare Conference AXGN +6.95% GlobeNewswire
Dec-03	Axogen Announces FDA Approval of Biologics License Application for AVANCE (acellular nerve allograft-arwx) AXGN +15.97% GlobeNewswire
Nov-04	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences AXGN GlobeNewswire
Oct-29	Axogen, Inc. Reports Third Quarter 2025 Financial Results AXGN +23.06% GlobeNewswire
Oct-15	Axogen, Inc. to Report 2025 Third Quarter Financial Results on October 29, 2025 AXGN GlobeNewswire
Aug-27	Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences AXGN GlobeNewswire
Aug-25	Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft AXGN -9.04% GlobeNewswire
Aug-05	Axogen, Inc. Reports Second Quarter 2025 Financial Results AXGN +9.32% GlobeNewswire
Jul-29	Axogen, Inc. to participate at the Canaccord Genuity 45th Annual Growth Conference AXGN GlobeNewswire
Jul-22	Axogen, Inc. to report 2025 second quarter financial results on August 5, 2025 AXGN +8.01% AXGN +7.34% GlobeNewswire
May-28	Axogen, Inc to Participate at Goldman Sachs Global Healthcare Conference AXGN GlobeNewswire
May-08	Axogen, Inc. Reports 2025 First Quarter Financial Results AXGN -23.18% GlobeNewswire
May-08	Axogen Announces Chief Financial Officer Transition AXGN -23.18% GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved.